Search results
Results from the WOW.Com Content Network
A study published in April 2021 by researchers from the COVID-19 Genomics United Kingdom Consortium, the AMPHEUS Project, and the Oxford COVID-19 Vaccine Trial Group indicated the Oxford–AstraZeneca vaccine showed somewhat reduced efficacy against infection with the Alpha variant (lineage B.1.1.7), with 70.4% efficacy in absolute terms ...
AstraZeneca’s COVID-19 vaccine provided strong protection against sickness and eliminated hospitalizations and deaths from the disease across all age groups in a late-stage study in the United ...
The clinical trial Phase I began on 15-16 August at Hanoi Medical University. Phase I was conducted on 100 healthy volunteers randomly assigned in a ratio of 3:1, i.e. 75% of them received the ARCT-154 vaccine and 25% received a placebo. The primary objective of the phase one trial was to assess safety and immunogenicity of the vaccine.
Silverwing is a children's novel written by Kenneth Oppel, first published in 1997 by HarperCollins. It tells the story of the Silverwings, a colony of silver-haired bats . Silverwing is the first installment of the Silverwing series, though it is chronologically the second novel in the sequence after Darkwing .
AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion. Icosavax is developing a combination vaccine ...
European pharma giant AstraZeneca Plc’s (NASDAQ:AZN) Covid vaccine, developed with the University of Oxford, is facing a class action lawsuit alleging its vaccine caused death and serious injury ...
Adding to AstraZeneca’s woes, the company had promised to ship 90 million doses of the vaccine to the EU in the first quarter of 2021, but less than a third of that number showed up.
Arcturus Therapeutics partnered with Singapore's Duke–NUS Medical School to develop a COVID-19 vaccine. [5] The company also partnered with Catalent , a contract development and manufacturing organization, to manufacture multiple batches of Arcturus' COVID-19 mRNA vaccine candidate.